Ceftobiprole: Difference between revisions
From IDWiki
Content deleted Content added
No edit summary |
|||
| Line 17: | Line 17: | ||
==Dosing== |
==Dosing== |
||
*Usual dose: 500 mg IV q8h over 2 hours |
*Usual dose (CAP, SSTI): 500 mg IV q8h over 2 hours |
||
*[[Staphylococcus aureus bacteremia]]: 500 mg IV q6h for 8 days followed by q8h |
*[[Staphylococcus aureus bacteremia]]: 500 mg IV q6h for 8 days followed by q8h |
||
=== Renal Dosing === |
=== Renal Dosing === |
||
{| class="wikitable" |
|||
!CrCl |
|||
* Required if CrCl <50 mL/min |
|||
!Usual Dose |
|||
!High Dose (MRSA) |
|||
|- |
|||
|≥50 |
|||
|500 mg q8h |
|||
|500 mg q6h for 8 days then q8h |
|||
|- |
|||
|30 to <50 |
|||
|500 mg q12h |
|||
|500 mg q8h for 8 days then q12h |
|||
|- |
|||
|15 to <30 |
|||
|250 mg q12h |
|||
|250 mg q8h for 8 days then q12h |
|||
|- |
|||
|<15 |
|||
| colspan="2" |250 q24h |
|||
|- |
|||
|IHD |
|||
| colspan="2" |250 q24h (after dialysis when given on dialysis days) |
|||
|} |
|||
==Safety== |
==Safety== |
||
Latest revision as of 18:16, 5 February 2026
Background
Mechanism of Action
- Binds to and inhibits PBP-2a on MRSA
- Binds to and inhibits PBP-2x on penicillin-resistant Streptococcus pneumoniae
Spectrum of Activity
- Active against MRSA, ampicillin-susceptible Enterococcus, and penicillin-resistant Streptococcus pneumoniae, as well as aerobic Gram-negative bacteria similar to other third-generation cephalosporins
- Not active against Pseudomonas, ESBL-producers, or AmpC-producers
Pharmacokinetics and Pharmacodynamics
- Crosses into CSF adequately
Dosing
- Usual dose (CAP, SSTI): 500 mg IV q8h over 2 hours
- Staphylococcus aureus bacteremia: 500 mg IV q6h for 8 days followed by q8h
Renal Dosing
| CrCl | Usual Dose | High Dose (MRSA) |
|---|---|---|
| ≥50 | 500 mg q8h | 500 mg q6h for 8 days then q8h |
| 30 to <50 | 500 mg q12h | 500 mg q8h for 8 days then q12h |
| 15 to <30 | 250 mg q12h | 250 mg q8h for 8 days then q12h |
| <15 | 250 q24h | |
| IHD | 250 q24h (after dialysis when given on dialysis days) | |
Safety
Adverse Drug Reactions
- Nausea, diarrhea, neutropenia (4%), dysgeusia
